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Summary The relationship between vascular endothelial growth factor (VEGF) and lymph node metastasis was studied in 90 cases of
primary lung cancerwithout distant metastasis. As a result ofquantitative reverse transcription polymerase chain reaction (RT-PCR) analysis,
the VEGF121 mRNA expression levels in lung cancer tissues with nodal metastasis (n = 35) were higher than in those without nodal
metastasis (n = 55). However, no significant difference could be found in VEGF121 mRNA expression levels as stratified by tumour size
(TiNOMO vs T2NOMO). Simultaneously, ten lymph nodes (four node positive and six node negative) together with the corresponding primary
lung tumours and adjacent normal lung tissue, were studied for VEGF expression. The VEGF mRNA expression in metastatic lymph nodes
was intense in three out of the four cases examined. Further, while VEGF expression levels in metastatic lymph nodes were conspicuously
higher than those for the primary site, all its expression levels in non-metastatic nodes were inferior to those of the primary tumours. Except
for macrophages, the VEGF antigen was identified mainly in the cytoplasm of metastatic cancer cells and the endothelial cells of blood or
lymphatic vessels in lymph nodes. Although the detailed mechanisms and the significance of strong VEGF expressions in metastatic lymph
nodes are still unknown, these data are consistent with a model whereby VEGF increases the opportunity for nodal metastasis through neo-
blood and lymphatic vessels.
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One of the most important factors that influences the survival of
surgical patients with primary lung cancer is the presence or
absence of nodal involvement. Little is known, however, about
mechanisms of lymph node metastasis. Tumour angiogenesis has
been considered to be an important step in a complex series within
the metastatic system, and some research has emphasized a signif-
icant correlation between the incidence of metastases and the
density of microvessels in primary tumours (Weidner et al, 1991;
Macchiarini et al, 1992; Craft et al, 1994; Yamazaki et al, 1994).
Among angiogenic factors, vascular endothelial growth factor
(VEGF) is known to be an endothelial cell-specific powerful
mitogen that is involved in tumour neovascularization. We previ-
ously examined mRNA expression for VEGF in resected primary
lung cancer tissue and in human lung cancer cell lines, and we
ascertained that VEGF mRNAs were dominantly expressed in
lung cancer as the transcripts for the secretory forms of VEGF,
VEGF121 and VEGF165 (Ohta et al, 1996a). Further, the
microvessel density, which includes lymphatic vessels, in a high-
VEGF121-expressing group was greater than that in the low-
expressing group (Ohta et al, 1996b). In non-small-cell lung
cancer, this powerful mitogen 'VEGF' may be an important prog-
nostic indicator for lung cancer. Interestingly, besides the inter-
action of angiogenic factors with the formation of blood vessels,
some research indicates a correlation between lymph node metas-
tasis and angiogenesis (Bosari et al, 1992; Guidi et al, 1994);
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however, with regard to this issue, research to the contrary also
exists (Yamazaki et al, 1994; Mattern et al, 1995). In this study, we
assessed the relationship between nodal status and the expression
ofVEGF in primary lung cancer.
MATERIALS AND METHODS
Tissue samples
Primary lung cancer tissues and adjacent normal lung tissues were
randomly obtained from90patients without distantmetastasis who
had received surgery in the Kanazawa University Hospital from
1987 to 1995. Simultaneously, ten lymph nodes, together with the
corresponding primary lung tumours and adjacent normal lung
tissues, were randomly obtained from ten patients (four were node
positive and six were node negative), and they were examined for
the expression of VEGF mRNA and of VEGF receptor (VEGFR)
mRNA. Sample organs were quickly frozen and stored at - 80°C
after resection. First, we reviewed the haematoxylin and eosin-
stained slides of the tumour specimens to confirm the histological
types ofthe frozen tumour tissue. The lymph node metastasis was
ascertained histopathologically by the haematoxylin and eosin
staining. For the frozen lymph node samples from ten patients, we
also assessed micrometastasis by amplification of keratin 19
mRNA using the reverse transcription polymerase chain reaction
(RT-PCR) technique. The pathological types were 44 adenocarci-
nomas (Ad), 30 squamous cell carcinomas (Sq), six large-cell
carcinomas (L), two adenosquamous carcinomas (As), one adenoid
cystic carcinoma (Ac) and seven small-cell carcinomas (S). The
pathological stage was classified as stage I in 46 patients (Ad, 23;
Sq, 15; As, one, L, one; Ac, one; and S, five), II in seven (Ad,
three; Sq, four), IIIA in 23 (Ad, 11; Sq, eight; As, one; L, two; and
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S, one) and IIIB in 14 (Ad, seven; Sq, three; L, three; and S, one)
according to the Japanese Lung Cancer Society classification.
RT-PCR analysis
Total RNA was extracted from each resected tissue using a RNA
extraction reagent, Isogen (Nippon Gene, Tokyo, Japan), according
to the standard acid guanidium-phenol-chloroform method. Total
RNA (1 ,ug) was denatured together with oligo-dT primer
(50 pmol) for 15 min at 68°C. After this was chilled on ice for
5 min, poly(A)+ RNA was reverse transcribed at 42'C for 90 min
in RT solution [50 mm Tris-HCl, pH 8.3, 40 mm potassium chlo-
ride, 8 mm magnesium chloride, 0.5 mm each dNTP, 225 jg ml-'
bovine serum albumin, 5 mm dithiothreitol, 20 units of RNAasin
(Promega Biotec, Madison, WI, USA) and 4 units ofAMV reverse
transcriptase (Life Science, Petersburg)] with a total volume of
20 ,ul. The cDNA was incubated at95°C for 5 min to inactivate the
reverse transcriptase. It served as a template DNA for 30 rounds of
PCR amplification. The PCR was carried out after adding 80 ,l of
the PCR mixture [50 mm Tris-HCl pH 8.3, 40 mm potassium chlo-
ride, 8 mm magnesium chloride, 0.5 mm each dNTP, 50 pmol each
of the sense and the antisense primer and 2.5 units of Taq poly-
merase (Takara, Kyoto, Japan)]. Amplification was performed for
1 min at 94°C, 1.5 min (last two cycles, 2 min) at 58°C and 2 min
(last two cycles, 5 min) at 72°C for VEGF; for 40 s (last three
cycles, 1.5 min) at 94'C, 1.3 min (last three cycles, 2 min) at 48°C
and 1.2 min (last three cycles, 2 min) at 72°C for VEGFRs [fns-
like tyrosine kinase 1 (flt-i), fins-like tyrosine kinase 4 (flt-4)
and kinase insert domain-containing receptor (KDR)]. PCR
primers were 5'-GAAGTGGTGAAGTTCATGGATGTC-3' and
5'-CGATCGTTCTGTATCAGTCTTTCC-3' for VEGF cDNA,
according to the VEGF gene structure (Tischer et al, 1991);
5'-GAGAATTCACTATGGAAGATCTGATTTCTTACAGT-3'
and 5'-GAGCATGCGGTAAAATACACATGTGCTTCTAG-3' for
flt-1; 5'-AGCCATTCATCAACAAGCCT-3' and 5'-GGCAACA-
GCTGGATGTCATA-3' for flt-4; 5'-TATAGATGGTGTAACC-
CGGA-3' and 5'-TTTGTCACTGAGACAGCTTGG-3' for KDR;
and 5'-AGGTGGATTCCGCTCCGGGCA-3' and 5'-AThTTCCT-
GTCCCTCGAGCA-3' for keratin 19 (Stasiak et al, 1987). For
Table 1 Basic clinical background factors of the 90 lung cancer patients
Node-positive Node-negative
patients patients
No. of patients 35 55
Mean age (years) 62.8 ± 7.8 65.0 ± 9.7
Male-female 26:9 39:16
Tumour size
<3cm 7 22
> 3 cm 28 33
Histology
Adenocarcinoma 17 27
Squamous cell carcinoma 12 18
Large-cell carcinoma 3 3
Adenosquamous cell carcinoma 1 1
Small-cell carcinoma 2 5
Other 0 1
Pathological stage
0 46
11 6 1
IIIA 17 6
IIIB 12 2
Southern blot analysis, the PCR products were electrophoresed
through a 1.0% agarose gel and were transferred to a nylon
membrane filter. After hybridization with a 32P-end-labelled probe
that was specific for the target cDNA fragments, all of the blots
were exposed to Kodak XAR film with an intensifying screen at
-80°C. The measurement of radioactivity was carried out
using a Fujix BAIO0 Bio-image-Analyser (Fuji Photo Film,
Hamamatsu, Japan). The probe oligonucleotides used were
VEGF, 5'-GAGATGAGCTTCCTACAGCACAAC-3'; flt-i, 5'-
GAGCTGGAAAGGAAAATCGCGTGCTGCTCC-3'; flt-4, 5'-
TTCCTTTCCAACCCCTTCCTGGTGCACATC-3'; and
KDR, 5'-ATCCAGTGGGCTGATGACCAAGAAGAACAG-3'.
Quantitative RT-PCR assay was performed as described previously
(Ohta et al, 1996a). Briefly, we prepared a precise dilution series
for each template cDNA. The amount ofradioactivity was plotted
against the template concentration, and we confimned that PCR
products were linearly accumulated. We used the sample data that
were on the line and avoided the sample data on the plateau level.
The intensity of VEGF mRNA expression was standardized using
the P-actin mRNA signal as an internal control. The sum of the
standardized intensities of both the tumour tissue and the corre-
sponding adjacent normal lung tissue were calculated as the total
intensity of the VEGF mRNA expression levels. Differences in
intensity were analysed using the Mann-Whitney U-test. The
criterion for statistical significance was P < 0.05.
Immunohistochemical staining
VEGF antigen expressions in the lymph nodes were assessed using
ten lymph nodes. The primary antibody used in this study was a
mousepolyclonal antibody at a 1:100dilutionforVEGF(SantaCruz
Biotechnonology, Santa Cruz, CA, USA). Paraffin sections were
deparaffinized and immunohistochemical staining was performed
using the immunoperoxidase technique. Thatis, endogenous peroxi-
dase was blocked by treatment with 0.3% hydrogen peroxide in
methanol for 10 min, and the specimens were washed with
Dulbecco's phosphate-buffered saline (pH 7.2) without calcium ion
or magnesium ion (PBS-). The sections were incubated with normal
goat serumdilutedtenfoldwithPBS-for 15 min atroomtemperature
to achieve blocking. Afterthey were washed with PBS-, the sections
reacted with antibodies for 1 h. Then, they were washed with PBS-
and reacted with biotin-labelled goat anti-mouse immunoglobulin
(Dako, Carpinteria, CA, USA) for30min atroomtemperature. After
they were washed with PBS-, avidin-biotin-peroxidase complex
was added and colour was developed by 3-3'-diaminobenzidine
(Sigma, St Louis, MO, USA) with 0.03% hydrogen peroxide.
Counterstaining was done with haematoxylin. The negative control
used all ofthe reagents except forthe primary antibody.
RESULTS
VEGF mRNA expression was examined in both tumour tissue and
adjacent normal lung tissue obtained from 90 primary lung cancer
patients. VEGF mRNAs were predominantly expressed as tran-
scripts for VEGF121 and VEGF165, the secretory forms ofVEGF.
Variable levels of VEGF transcripts were detected in 73 (78.5%)
lung cancer tissue samples. The positive ratios of VEGF mRNAs
in tumours according to pathological types were 75.0% (33 out of
44) in adenocarcinomas, 80.0% (24 out of 30) in squamous cell
carcinomas, 83.3% (five out of six) in large-cell carcinomas, 50%
(one out of two) in adenosquamous carcinomas and 71.4% (five
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Figure 1 RT-PCR analysis of VEGF and its receptor fit-1 mRNAs in lymph nodes (LN), corresponding lung cancer tissue (T) and adjacent normal lung tissue
(N). Among the ten lymph node samples, four from node-positive patients were metastatic (samples 1-4) and six from node-negative patients were non-
metastatic (samples 5-10). This assessment of lymph node metastasis was performed by histopathological examination using haematoxylin and eosin staining,
and the RT-PCR method for the detection of keratin 19 mRNA was used as a sensitive assay for the micrometastasis. Other receptors (flt-4 and KDR) were not
found in this study
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Figure 2 Staining of VEGF using polyclonal antibody in metastatic lymph nodes. Cytoplasmic staining was positive in metastatic tumour cells (A) and
endothelial cells in lymphatic vessels (B)
out of seven) in small-cell carcinomas. Among adjacent normal
lung tissues, ten had especially strong VEGF mRNA expression
(more than 5.0 x 10-2 as a relative ratio of the PCR products of
VEGF121 to those of the f-actin, as calculated using the PCR
products accumulated linearly). Except for two out of the ten
cases, all had advanced lung cancer (stage I, two; IIIA, three; and
IIIB, five); four cases with carcinomatosa pleuritis were included.
The VEGF121 mRNA expression levels in the lung cancer tissue
of the node-positive patients (n = 35) and the node-negative
patients (n = 55) were assessed. The basic clinical features of
these patients are shown in Table 1. The mean 'total intensities'
(mean ± s.d.) of VEGF121 in these two groups were 23.2 ± 39.9
and 8.8 ± 17.9 respectively. The difference was of borderline
significance (P = 0.051). When stratified by nodal status using
patients without distant metastasis, the values wereNI, 12.0+ 14.9
(n = 7); N2, 21.2 ± 36.2 (n = 21); and N3, 40.5 ± 66.1 (n = 7). We
could find no significant difference in the relative intensity of the
VEGF121 mRNA expression levels when stratifiedby tumour size:
pTl (> 3 cm) NOMO patients (n = 22) and pT2 (< 3 cm) NOMO
patients (n = 25) [(16.5 ± 20.8) x 10-2 vs (17.4 ± 22.4) x 10-2].
Ten lymph nodes, the corresponding tumour tissue and the
corresponding adjacent normal lung tissue obtained from the ten
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patients with primary lung cancer were examined for VEGF and
VEGF receptor (flt-i, flt-4 and KDR) mRNA expression. After
histopathological examination of these ten lymph node samples,
the four from the node-positive patients were defined as metastatic
and the six from the node-negative patients as non-metastatic. A
pathological assessment of the lymph node metastasis agreed
completely with the results from the RT-PCR method for the
detection of keratin 19 mRNA as a sensitive assay for the
micrometastasis (data not shown). VEGF mRNAexpression could
be found in all ten lymph nodes; the expression levels for the
metastatic lymph nodes were intense (Figure 1, Table 2). The rela-
tive intensity ofthe VEGF mRNA in the lymph nodes was greater
than those in the corresponding tumour tissue in three out of the
four metastatic lymph nodes. On the other hand, in all six patients
without node metastasis, the VEGFexpression levels in the lymph
nodes were inferior to those of the tumour tissues. Immuno-
histochemically, VEGF antigen was found in the cytoplasms of
metastatic tumour cells and the endothelial cells of lymphatic or
blood vessels in metastatic lymph nodes (Figure 2), together with
weak staining in macrophages. In non-metastatic lymph nodes, its
expression was found weakly in the endothelial cells ofthe vessels
and macrophages. Among the three kinds of VEGFRs, only flt-I
mRNA could be detected in some of the node-positive and node-
negative lymph nodes (Figure 1). The expression of flt-4 mRNA
and KDR mRNA was not found.
DISCUSSION
In 90 lung cancer tissue samples, the expression of VEGF mRNA
was found at a high rate, independent of histological subtypes.
Among the four splicing variants, VEGF121 and VEGF165 were
the dominant types. On the other hand, overexpression in adjacent
normal lung tissue was also found, and its expression level was
especially high in ten cases. It has become clear that many of the
cases with an overexpression of VEGF in adjacent normal lungs
were advanced diseases and included four cases with pleural
disseminations. In these cases, a 'relative intensity' (calculated as
the ratio of tumour vs corresponding normal lung tissue) does not
seem to be appropriate because, as VEGF may be involved in
tumour angiogenesis, not only through autocrine systems but also
through paracrine systems, the expression levels in normal lung
tissue should be taken into consideration in the assessment of
mitogenic activity. In this study, the intensity of the VEGF121
mRNA expression levels was calculated by the sum ofthe intensi-
ties of both the tumour tissue and the corresponding adjacent
normal lung tissue by using the quantitative RT-PCR method. As
to the accuracy of the RT-PCR method for the assessment of
VEGF expressions in lung cancer, we have already confirmed that
the VEGF antigen levels that were detected by immunohistochem-
ical examination were mostly in agreement with mRNA expres-
sion levels that were detected by the quantitative RT-PCR method
(Ohta etal, 1996a). We consider that the VEGF mRNA expression
levels defined here by RT-PCR come to a reliable standard.
Two main channels may offer possible routes for lymph node
metastasis. The first channel is of an anatomical nature and is by
means ofblood circulation into the lymphatic hilum. Tumour cells
in the blood can be transported and can be arrested in the lymph
nodes using this channel. With the increasing number of tumour
cells in the blood, the frequency of nodal involvement may rise.
Consequently, tumour angiogenesis may have an indirect influence
on nodal metastasis through this channel in an intersection between
the blood and the lymphatic circulations. The second channel is by
way of tumour invasion into the lymphatic vessels. Here, the
following hypothesis is considered: if the number of lymphatic
vessels increases in a tumour, i.e. if 'lymphogenesis' occurs within
the tumour, not only in pre-existing lymphatic vessels but also in
those that are newly formed or are becoming neolymphatic, this
may be a channel for lymph node metastasis. Although the effects
of angiogenic factors on the lymphatic vessels is not clear, there is
a possibility that they act as mitogens for endothelial cells in
lymphatic vessels. If this hypothetical channel does exist, tumour
angiogenesis may be directly involved in lymph node metastasis.
In our study, VEGF expression levels in lung cancers with nodal
metastasis were greater than in those without nodal metastasis. As
we could find no significant difference in the relative intensity of
VEGF121 mRNA expression levels when stratified by tumour
size, this indicates the possibility that VEGF expression in the
primary site effects lymph node metastasis independent of tumour
size. It is unclear whether it depends on the direct or the indirect
channels. Because of the difficulty in making an exact distinction
between blood and lymphatic microvessels, we cannnot exactly
assess lymphatic vessel density. Microvessel density has usually
been generalized by staining endothelial cells for factor VIII,
CD31, etc., and the relationship between neovascularity and VEGF
has been ascertained in lung cancer (Mattem et al, 1995; Ohta et al,
1996b). Here, we must emphasize that immunohistochemical
staining with any reagent might recognize both blood and
lymphatic microvessels; hence, the assessment of microvessel
density inevitably includes a fraction that is lymphatic. Therefore,
the possibility remains that the mitogenic activity ofVEGF acts on
lymphatic endothelial cells in a primary site and leads to lympho-
genesis. Some research has indicated a relationship between
microvessel density and lymph node metastasis (Weidner et al,
1992; Bosari et al, 1992). Additional research is required to deter-
mine whether or not 'lymphogenesis' occurs.
VEGF mRNA expressions were found in lymph nodes. In this
study, to obtain an exact diagnosis of nodal metastasis including
micrometastasis, we examined keratin 19 mRNA expression using
the RT-PCR technique. As a sensitive assay for the detection of
micrometastasis, the RT-PCR method with a target for keratin 19
has been successfully applied to the detection of lymph node
micrometastasis. This method can detect nodal metastasis more
correctly and sensitively than histological examination (Noguchi et
al, 1996). In our study, keratin 19 mRNA was found in four lymph
nodes that had been histologically diagnosed as metastatic but was
not found in six that had been histologically diagnosed as non-
metastatic. We came to the conclusion that lymph nodes that had
beenobtainedfromthenode-negativepatients were all truenegative.
The VEGF expression levels in the metastatic lymph nodes
were all intense. Especially noteworthy is that the mRNA expres-
sion levels in the metastatic nodes were superior to those in the
primary site in three out of the four cases. On the other hand, the
expression levels in the non-metastatic lymph nodes were all
inferior to those in the primary site. Surprisingly, in one case with
nodal metastasis (patient 2 in Figure 1), the VEGF mRNA expres-
sion was weak in the primary site but was strong in the metastatic
node. Here, the primary lung tumour was a large-cell carcinoma in
periphery and was small in size (1.0 x 0.6 x 0.6 cm) but had bulky
mediastinal lymph nodes at multiple levels. With regard to this
curious inter-relation, Ellis et al (1995) studied VEGF expression
in both non-metastatic and metastatic human colon cancer cell
lines and concluded that the VEGF expression in the metastatic
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cell lines was higher than that in its non-metastatic counterparts.
Tumour cells with VEGF expression may metastasize selectively.
Immunohistochemically, VEGF antigen was found mainly in the
cytoplasms of metastatic tumour cells and in the endothelial cells
in the lymphatic orblood vessels in the metastatic lymph nodes. In
non-metastatic lymph nodes, its expression was weakly localized
in the endothelial cells of vessels and macrophages. We also
studied flt-1, flt-4 and KDR mRNA expression. In some of the
lymph nodes, the flt-I expression was found irrespective of the
expression in the primary lesion. However, its expression state
does not seem to be connected to nodal metastasis. Flt-1 that orig-
inates from metastatic tumours may not be important as regards
nodal involvement. Concerning VEGF function, Gabrilovich et al
(1996) reported some interesting results. According to their
research, VEGF may play a broader role in the pathogenesis of
cancer, namely a role in allowing malignant tumours to avoid the
induction of an immune response. As regards the significance of
VEGF expression within lymph nodes, another function that is
different from the proliferation ofendothelial cells may exist.
In conclusion, strong VEGF expression in primary sites and
nodal metastasis are correlated, and expression in metastatic
lymph nodes has atendency to increase compared with thatin non-
metastatic lymph nodes. Although the detailed mechanisms and
the significance of the strong VEGF expression in metastatic
lymph nodes are still unknown, our results do not exclude the
possibility that VEGF is directly concerned with lymph node
metastasis in lung cancer. Recently, we discovered experimentally
the strong inhibitory action of an anti-angiogenic agent on lymph
node metastasis using a quantitative assay in a metastatic model
system (Ohta et al, 1997). Of course, we cannot ignore the 'seed
and soil' theory (Paget, 1889) as regards the formation of metas-
tasis, but these data are consistent with a model whereby VEGF
increases the opportunity of nodal metastasis through the neo-
blood and lymphatic vessels.
ABBREVIATIONS
VEGF, vascular endothelial growth factor; RT-PCR, reverse tran-
scription polymerase chain reaction; VEGFR, VEGF receptor;
flt-l,fins-like tyrosine kinasae 1; flt-4,fins-like tyrosine kinase 4;
KDR, kinase insert domain-containing receptor.
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